ALT — Altimmune, Inc.

Altimmune, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: $27.4 million for 2025, or $0.27 per share, compared to a net loss of $23.2 million, or $0.33 per share in 2024.
• R&D Expenses: $18.4 million in Q4 2025, down from $19.8 million in Q4 2024, primarily due to the completion of the Phase IIb trial.
• G&A Expenses: Increased to $10.5 million in Q4 2025 from $5.1 million in Q4 2024, attributed to executive transition costs and higher professional fees.
• Cash Position: Approximately $274 million at year-end 2025, with a pro forma cash position of about $340 million post recent capital raises, providing a runway into 2028.

2. Strategic Updates and Business Highlights

• PEMB Development: PEMB received FDA Breakthrough Therapy designation for NASH, with promising Phase IIb MATCH trial results showing early NASH resolution and antifibrotic activity.
• Phase III Trial Preparation: The company is finalizing the protocol for a pivotal Phase III trial, aiming to enroll approximately 1,800 patients with moderate to advanced fibrosis (F2/F3 NASH).
• Market Research Insights: Feedback from healthcare professionals indicates a significant unmet need for therapies addressing tolerability issues and muscle preservation in NASH patients, which PEMB aims to fulfill.

3. Forward Guidance and Outlook

• Phase III Trial Launch: Expected to initiate in 2026, with detailed planning underway and alignment with FDA on trial design.
• Data Reporting: Anticipated top-line data from the Phase II AUD trial in Q3 2026, with ongoing enrollment in the ALD trial expected to complete in 2026.
• Financial Strategy: The company remains committed to securing additional capital as needed to support clinical programs and maintain operational strength.

4. Bad News, Challenges, or Points of Concern

• Increased G&A Expenses: The significant rise in G&A expenses raises concerns about operational efficiency and cost management.
• Regulatory Risks: While the FDA has provided guidance, the reliance on biopsy-driven endpoints for approval poses risks, especially if the agency's stance on non-invasive tests (NITs) changes.
• Competitive Landscape: The emergence of new therapies targeting NASH could pose competitive pressures, particularly if they demonstrate superior efficacy or tolerability.

5. Notable Q&A Insights

• FDA Discussions: The company has not discussed the new single pivotal framework with the FDA, indicating that their current path remains unchanged.
• NITs as Registrational Endpoints: The FDA deemed it premature to consider NITs for registrational endpoints, maintaining the focus on biopsy-driven assessments.
• Muscle Preservation: Questions regarding muscle preservation highlighted its importance in the NASH population, with ongoing discussions on how to incorporate this into the Phase III trial.
• Enrollment Strategies: The company plans to assess AUD data before proceeding with ALD, indicating a strategic approach to trial timelines and resource allocation.

Overall, Altimmune is positioned for significant developments in 2026, particularly with PEMB, but must navigate financial management and competitive pressures effectively.